REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

"Conflict of interest Tatsuya Yamashita has received honoraria from Bayer Yakuhin Ltd. and Eisai Co., Ltd. Masatoshi Kudo has held leadership positions at, or has had advisory roles at Kowa Company, Ltd., MSD, BMS, Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., and TAIHO PHARMACEUTICAL CO., LTD., has received honoraria from Bayer Yakuhin Ltd., Eisai Co., Ltd., and MSD, and has received commercial research funding from Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., MSD, Eisai Co., Ltd., Bayer Yakuhin Ltd., and Abbvie. Kenji Ikeda has received honoraria from Dainippon Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Namiki Izumi has no conflicts of interest to declare. Ryosuke Tateishi has received honoraria from Bayer Yakuhin Ltd., MSD, Eisai Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. and has also received commercial research funding from Kyowa Hakko Kirin Co., Ltd. Masafumi Ikeda has received honoraria from Bayer Yakuhin Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Novartis, and has received commercial research funding from ONO PHARMACEUTICAL CO., LTD., AstraZeneca K.K., Zeria Pharmaceutical Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Merck Serono, Bayer Yakuhin Ltd., Yakult Honsha Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., Baxter, ASLAN Pharmaceuticals, NanoCarrier Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Hiroshi Aikata has no conflicts of interest to declare. Yasunori Kawaguchi has no conflicts of interest to declare. Yoshiyuki Wada has received honoraria from Bayer AG and commercial research funding from AstraZeneca K.K., BeiGene Ltd., Ely Lilly & Co., Pfizer Inc., and Bayer AG. Kazushi Numata has no conflicts of interest to declare. Yoshitaka Inaba has no conflicts of interest to declare. Ryoko Kuromatsu has no conflicts of interest to declare. Masahiro Kobayashi has received honoraria from Eisai Co., Ltd. Takuji Okusaka has received commercial research funding from Novartis Pharma K.K., Eli Lily Japan K.K., Dainippon Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Eisai Co., Ltd. Toshiyuki Tamai is employed by Eisai Co., Ltd. Chifumi Kitamura is employed by Eisai Co., Ltd. Kenichi Saito is employed by Eisai Co., Ltd. Katsuya Haruna is employed by Eisai Co., Ltd. Kiwamu Okita has no conflicts of interest to declare. Hiromitsu Kumada has received honoraria from MSD, Sumitomo Dainippon Pharma Co., Ltd., Bristol-Myers Squibb, Abbvie, and Gilead Sciences, Inc."

"Funding The study was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Editorial assistance was funded by Eisai Co., Ltd., Japan."

"Trial registration ID ClinicalTrials.gov. No. NCT01761266."